Ohio State University

Ohio State University Tumor Boards

Questions discussed in this category

How would you treat patient with a recurrent thymic carcinoma after prior surgery and concurrent chemoradiation?

Chemoradiation completed 1.5 years prior

How would you manage a middle aged woman with history of severe alcoholic liver cirrhosis and a small node negative ER/PR positive, HER2 negative breast cancer?

How would you balance the competing risks of these two diagnoses in her treatment?

1 Answer available

How would you treat oligometastatic NSCLC (brain and bone) with Non-V600E BRAF mutations?

SRS done to the single brain met, PD-L1 5%, BRAF G469A mutation

1 Answer available

After WBRT, what systemic therapy would you favor for maximal CNS penetrance in a patient with triple negative metastatic breast cancer and multifocal CNS disease?

Is there any evidence for sacituzumab govitecan (IMMU-132) in this situation with progressive systemic disease after prior anthracycline and taxane?

1 Answer available

With the approval of capmatinib, how would you approach a newly diagnosed metastatic NSCLC with MET Exon 14 skipping mutation?

1 Answer available

How long should breast cancer patients, whose surgeries are delayed due to COVID-19, remain on neoadjuvant endocrine therapy?

For patients with low risk, early stage, hormone receptor positive, HER2 negative breast cancer who initiated endocrine therapy in order to delay thei...

3 Answers available

How would you approach a stage 1 HR+/HER2- pre-menopausal patient <50 years old with Oncotype DX RS of 24?

Would you offer this patient chemotherapy? What are your thoughts about OFS plus AI and avoiding chemotherapy?

3 Answers available

Would you continue pembrolizumab in an asymptomatic metastatic NSCLC patient with high PD-L1, who develops granulomatous mediastinal lymphadenopathy biopsy proven as sarcoid?

1 Answer available

How would you treat a patient with metastatic NSCLC on pembrolizumab with a sustained complete response, now with 2 isolated small liver lesions?

Would you treated with local therapies (RFA or SRS) and continue pembrolizumab or would you move to second line treatment?

1 Answer available

In which group of patients you would send for RNAseq for translocations/fusions that might be missed by NGS in advanced NSCLC?

4 Answers available

How would you approach a patient with metastatic squamous NSCLC that progressed on carbo/paclitaxel/pembro and has a FGFR3 S249C mutation?

Especially if you don't have trials available at the moment. Would you try off-label erdafitinib (given recent data on bladder cancer) or 2nd line ge...

1 Answer available

How would you approach frontline treatment for a metastatic non-squamous NSCLC patient with MET amplification and a concurrent KRAS mutation?

1 Answer available

How would you approach frontline treatment of a patient with metastatic non-squamous NSCLC with ERBB2 amplification and PD-L1 > 50%?

In the absence of a frontline clinical trial, would you treat with carboplatin+pemetrexed+pembrolizumab or consider IMPOWER 150 or other?

3 Answers available

How would you approach metastatic adenocarcinoma of the lung with ROS1 rearrangement by FISH and EGFR L858R mutation by NGS?

2 Answers available

How would you treat a case of mixed histology NSCLC/SCLC that rapidly progresses following chemoradiation and durvalumab?

In a patient with lung cancer with both NSCLC and SCLC components, would you offer carbo/pem/pembro or carbo/etoposide/atezolizumab? Or any other alte...

2 Answers available

How would you treat a metastatic lung adenocarcinoma with MET exon 14 skip mutation on ctDNA, negative tissue NGS and PD-L1 of >50%?

The NCCN guidelines regard MET exon 14 skip mutation as an emerging biomarker but no formal recommendation to start crizotinib. If high P...

1 Answer available

What is your preferred induction chemotherapy for stage IIIA NSCLC squamous and adenocarcinoma?

Is there any advantage of one regimen over the others?

1 Answer available

How would you approach a patient with Stage III EGFR+ NSCLC who develops oligometastatic disease while on consolidation durvalumab?

Given the potential high risk of developing pneumonitis with TKI post checkpoint inhibitor, do you avoid TKIs and try a different regimen (ex carbo/pa...

1 Answer available

How do you manage patients with HER2 positive breast cancer who have progressive CNS metastases after prior exposure to pertuzumab, trastuzumab, TDM1, and lapatinib?

1 Answer available

Do you give systemic therapy for triple negative breast cancer with brain metastasis and no other sites of disease?

Following SRS to the brain lesions, is it safe to closely follow the patient for recurrence?

4 Answers available

Based on new data from ASCO2019, would you consider gefitinib +chemotherapy instead of osimertinib frontline for EGFRm metastatic NSCLC pts?

http://abstracts.asco.org/239/AbstView_239_262655.html

5 Answers available

How would you manage a locally advanced TNBC and a malignant appearing renal mass suspicious for a synchronous renal cell carcinoma?

1 Answer available

In a germline BRCA2 positive pt with NSCLC after chemoIO frontline and taxotere as a second line, would you consider PARP inhibitors?

If so, would you combine them vs monotherapy? Patient ECOG is 1

1 Answer available

Would you offer adjuvant chemotherapy in a patient with extensive LCIS/DCIS s/p mastectomy and multiple positive lymph nodes due to surgical seeding?

If so, would you treat as node + BC with anthracycline and taxane regimen or non-anthracycline regimen (i.e docetaxel and cyc...

1 Answer available

When would you consider neratinib in a patient with locally advanced HR positive, Her2 positive breast cancer who received one year of trastuzumab and pertuzumab?

1 Answer available

After progression on osimertinib, do you recommend overlapping TKI with 2nd line chemotherapy to avoid accelerated disease progression?

Retrospective data suggest clinically significant disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung canc...

1 Answer available

With the approval of frontline pembrolizumab monotherapy for advanced NSCLC with PD-L1 of 1% or above, how do you select who gets Chemo-IO versus pembro monotherapy if PD-L1 between 1-49%?

1 Answer available

Should GnRH agonist therapy be continued beyond 5 years (along with an aromatase inhibitor) in young pre-menopausal women with high risk breast cancer who continue to have ovarian function at 5 years of endocrine treatment?

1 Answer available

What would you use as next line of treatment for a patient with ROS1 positive metastatic NSCLC progressing on crizotinib?

Would you use Lorlatinib , chemotherapy, immunotherapy or Chemo- immunonotherapy?

1 Answer available

How would you advise a pre-menopausal, HR-, HER2+ BC with treated brain metastases and NED while on trastuzumab/pertuzumab who wants to conceive?

1 Answer available

When do you consider it too late after breast surgery to offer adjuvant chemotherapy to a patient with high risk non-metastatic breast cancer?

Is there a point at which there may be no benefit? More than 3 months from breast surgery? 6 months? 1 year?

1 Answer available

How would you treat a pregnant woman in the third trimester with locally advanced, hormone receptor positive, HER2 positive breast cancer?

Would you maintain dose density of chemotherapy and use peg-filgrastim prior to delivery of the baby? Would you defer taxane and anti-HER2 therapy unt...

2 Answers available

Would you consider adjuvant chemotherapy for a patient with T1a N0 triple negative breast cancer?

If so, what would be the regimen that you would consider and what factors would sway you for or against chemotherapy for such patients?

1 Answer available

Do you offer pembrolizumab monotherapy or carbo-pemetrexed-pembrolizumab to a patient with Stage IV large cell NSCLC with PD-L1 of 80% and KRAS+STK11 mutation?

Some retrospective data reports that STK11 (AKA LKB1) makes NSCLC resistant to immunotherapy.

2 Answers available

How would you approach a biopsy proven NSCLC patient with mediastinum negative disease and contralateral suspicious spiculated PET avid nodule without pathologic diagnosis?

No other site of metastatic disease. It is unclear if this situation should be managed as two separate primaries or metastatic disease.

2 Answers available

How do you manage elderly patients with borderline PS and ER+ inflammatory breast cancer without metastasis?

Would you consider neo-adjuvant chemotherapy or treat with endocrine therapy?

1 Answer available

In patients who develop a VTE on palbociclib, do you discontinue therapy or continue as long as the patient is receiving adequate anticoagulation therapy?

1 Answer available

Do you routinely offer neo-adjuvant chemotherapy for patient with triple negative metaplastic breast cancer?

2 Answers available

Would you re-challenge patients with an EGFR TKI beyond progression if repeated biopsies show redemostration of a sensitizing mutation (exon 19 deletion) and no other resistance mechanisms?

1 Answer available

What would you choose as the second line treatment option for a stage IV EGFR mutant lung adenocarcinoma that has progressed on osimertinib?

Carbo/pemetrexed/pembrolizumab, carbo/pemtrexed without immunotherapy or second line immunotherapy (Nivo, Pem or atezolizumab)?

1 Answer available

Would you send a lung cancer patient for genetic counseling/germline mutation testing if they are harboring mutations in NGS with variation allele frequency between >=50%?

Ex. TP53, BRCA, T790M, or another? As of now, T790M mutation is one of the few de novo mutations found in treatment naïve patients th...

2 Answers available

What would be your next line of treatment for NSCLC adenocarcinoma that has recurred after chemoradiation with cis/etoposide?

PD-L1 < 50% and no targetable mutations. Would you use carbo/pemetrexed/pembrolizumab or Nivolumab or pembrolizumab?

1 Answer available

How would you treat metastatic NSCLC in a non-smoker with bone biopsy showing adenocarcinoma of lung origin but inadequate tissue for mutational panel or PD-L1?

Lung primary is inaccessible for biopsy and metastatic sites are only 2 small bone lesions. In a non-smoker, a driver mutation is suspected but would ...

2 Answers available

Is it safe and/or necessary to combine osimertinib and carboplatin/paclixel for a patient with stage IV EGFR mutated NSCLC and advanced ovarian carcinoma?

Certainly ovarian cancer will respond to carboplatin and paclitaxel and it sounds like a reasonable chemotherapy to give to a stage IV NSCLC, however ...

1 Answer available

In which patients with stage IV NSCLC and PD-L1 TPS >50% plus concomitant autoimmune disease is it considered safe to give immune checkpoint blockers?

1 Answer available